Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - GOLD executive summary

被引:4936
作者
Rabe, Klaus F.
Hurd, Suzanne
Anzueto, Antonio
Barnes, Peter J.
Buist, Sonia A.
Calverley, Peter
Fukuchi, Yoshinosuke
Jenkins, Christine
Rodriguez-Roisin, Roberto
van Weel, Chris
Zielinski, Jan
机构
[1] Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Global Initiat Chron Obstruct Lung Dis, Gaithersburg, MD USA
[3] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[4] Natl Heart & Lung Inst, London, England
[5] Oregon Hlth & Sci Univ, Portland, OR USA
[6] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England
[7] Asian Pacific Soc Respirol, Tokyo, Japan
[8] Woolcock Inst Med Res, Sydney, NSW, Australia
[9] Hosp Clin Barcelona, Barcelona, Spain
[10] Univ Nijmegen, Nijmegen, Netherlands
[11] Inst TB & Lung Dis, Warsaw, Poland
关键词
COPD; guidelines; human; chronic disease;
D O I
10.1164/rccm.200703-456SO
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization. Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials. In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S. National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications. The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001. The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared. GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines. We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD. Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem. The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.
引用
收藏
页码:532 / 555
页数:24
相关论文
共 266 条
[1]   Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease [J].
Aaron, SD ;
Vandemheen, KL ;
Hebert, P ;
Dales, R ;
Stiell, IG ;
Ahuja, J ;
Dickinson, G ;
Brison, R ;
Rowe, BH ;
Dreyer, J ;
Yetisir, E ;
Cass, D ;
Wells, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2618-2625
[2]   Lung function and long term exposure to air pollutants in Switzerland [J].
AckermannLiebrich, U ;
Leuenberger, P ;
Schwartz, J ;
Schindler, C ;
Monn, C ;
Bolognini, C ;
Bongard, JP ;
Brandli, O ;
Domenighetti, G ;
Elsasser, S ;
Grize, L ;
Karrer, W ;
Keller, R ;
KellerWossidlo, H ;
Kunzli, N ;
Martin, BW ;
Medici, TC ;
Perruchoud, AP ;
Schoni, MH ;
Tschopp, JM ;
Villiger, B ;
Wuthrich, B ;
Zellweger, JP ;
Zemp, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (01) :122-129
[3]   Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD [J].
Adams, SG ;
Melo, J ;
Luther, M ;
Anzueto, A .
CHEST, 2000, 117 (05) :1345-1352
[4]   Systemic effects of chronic obstructive pulmonary disease [J].
Agustí, AGN ;
Noguera, A ;
Sauleda, J ;
Sala, E ;
Pons, J ;
Busquets, X .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (02) :347-360
[5]  
Agusti Alvar G N, 2005, Proc Am Thorac Soc, V2, P367, DOI 10.1513/pats.200504-026SR
[6]   Clinical efficacy of anti-pneumococcal vaccination in patients with COPD [J].
Alfageme, I ;
Vazquez, R ;
Reyes, N ;
Muñoz, J ;
Fernández, A ;
Hernandez, M ;
Merino, M ;
Perez, J ;
Lima, J .
THORAX, 2006, 61 (03) :189-195
[7]  
ALFAYEZ SF, 1988, TROP GEOGR MED, V40, P115
[8]  
Allegra L, 1996, RESPIRATION, V63, P174
[9]  
Altose MD, 2000, NEW ENGL J MED, V343, P1902
[10]  
American Medical Association, 1994, GUID DIAGN TREATM NI